background
one
million
infect
sever
acut
respiratori
syndrom
corona
viru
confirm
pcrbase
assay
use
diagnosi
high
throughput
serolog
method
need
detect
antibodi
seroserveil
identif
seroconvers
potenti
plasma
donor
natur
immun
respons
pathogen
luminex
bind
assay
use
assess
presenc
antibodi
human
sera
uninfect
individu
specif
two
recombin
protein
find
fluorochromelabel
bead
coat
recombin
solubl
stabil
trimer
protein
ectodomain
central
portion
receptor
bind
domain
rbd
coat
bead
incub
sera
follow
incub
biotinyl
antihuman
total
ig
antibodi
phycoerythrin
pe
label
streptavidin
readout
use
luminex
analyz
clearli
differenti
sera
infect
uninfect
subject
delin
wide
rang
serum
antibodi
level
infect
subject
interpret
antibodi
assay
sera
identifi
individu
infect
seroconvert
well
subject
infect
recov
use
luminex
bind
ab
assay
advantag
run
approxim
hour
use
littl
antigen
permit
high
throughput
samplesday
amanat
f
nguyen
chromikova
v
et
al
serolog
assay
detect
seroconvers
human
medrxid
outbreak
infect
began
late
specimen
nasopharyng
swab
use
pcrbase
assay
test
presenc
viru
first
week
april
licens
test
presenc
serum
antibodi
protein
viru
first
approv
test
becom
avail
none
use
format
scale
mass
screen
need
implement
variou
public
health
measur
per
recent
pubm
search
less
studi
use
serolog
assay
publish
none
high
throughput
ad
valu
studi
high
throughput
antibodi
test
need
order
identifi
seroconvers
perform
serosurvey
identifi
potenti
donor
plasma
therapi
assess
preval
infect
popul
identifi
healthcar
worker
may
immun
studi
natur
immun
respons
pathogen
method
describ
detect
antibodi
patient
appli
hospit
refer
lab
allow
assess
present
past
infect
much
higher
number
donor
per
unit
time
assay
describ
heretofor
studi
show
test
magnet
bead
coat
solubl
form
spike
protein
use
test
presenc
antibodi
target
pathogen
platform
allow
effici
test
multipl
specimen
simultan
use
littl
nanogram
antigen
per
test
test
afford
possibl
larg
scale
econom
effici
antibodi
test
revers
transcript
polymeras
chain
reaction
rtpcr
test
current
use
qualit
detect
nucleic
acid
specimen
upper
lower
respiratori
tract
molecular
test
well
establish
use
clinic
laboratori
throughout
world
two
decad
contrast
test
serum
bodili
fluid
antibodi
ab
infecti
diseas
syphili
typhoid
diphtheria
use
centuri
antibodi
ab
assay
use
identifi
individu
infect
particular
pathogen
seroconvert
particularli
valuabl
exampl
identif
subject
asymptomat
viral
infect
recov
would
longer
posit
test
viral
nucleic
acid
would
also
particularli
use
serosurveil
identifi
donor
plasma
therapi
identifi
individu
potenti
immun
reinfect
antibodi
assay
thu
fill
essenti
gap
current
pandem
fact
one
studi
depend
time
test
postinfect
combin
use
rtpcr
ab
posit
provid
advantag
either
test
alon
other
describ
test
assess
presenc
ab
serum
plasma
use
enzymelink
immunosorb
assay
elisa
platform
recombin
form
protein
viru
andor
central
portion
molecul
identifi
receptor
bind
domain
rbd
consist
amino
acid
report
modif
elisa
assay
bead
label
particular
fluorochrom
signatur
coat
solubl
recombin
protein
rbd
incub
serum
biotinyl
antihuman
total
ig
ab
phycoerythrin
pe
label
streptavidin
readout
perform
laserbas
instrument
high
throughput
assay
offer
advantag
abl
prepar
antigenco
bead
thousand
test
singl
day
use
least
less
antigen
requir
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
elisa
set
hospit
region
refer
lab
result
specimen
per
day
gener
recombin
rbd
protein
produc
previous
describ
cell
thermofish
transfect
purifi
dna
use
expifectamin
transfect
kit
thermofish
solubl
version
spike
protein
includ
protein
ectodomain
amino
acid
ctermin
thrombin
cleavag
site
foldon
trimer
domain
hexahistidin
tag
protein
sequenc
modifi
remov
polybas
cleavag
site
rrar
two
stabil
mutat
wild
type
number
rbd
amino
acid
also
contain
hexahistidin
tag
supernat
transfect
cell
harvest
day
three
posttransfect
centrifug
cultur
g
minut
supernat
incub
ml
ninta
agaros
qiagen
one
two
hour
room
temperatur
next
graviti
flow
column
use
collect
ninta
agaros
protein
elut
protein
concentr
amicon
centrifug
unit
emd
millipor
resuspend
phosphat
buffer
salin
pb
human
sampl
bank
serum
sampl
obtain
studi
particip
enrol
two
irb
spread
usa
serv
neg
control
n
n
n
particip
provid
written
consent
studi
enrol
agre
sampl
bank
futur
research
use
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
bank
biospecimen
four
addit
deidentifi
serum
specimen
p
provid
clinic
patholog
laboratori
icahn
school
medicin
mount
sinai
tabl
provid
overview
serum
sampl
use
report
luminex
bind
ab
assay
antigen
includ
solubl
recombin
trimer
form
protein
recombin
rbd
protein
produc
mammalian
cell
describ
mspike
mrbd
antigen
coval
coupl
individu
carboxyl
xmap
bead
proteinmillion
bead
use
twostep
carbodiimid
reaction
xmap
ab
coupl
abc
kit
accord
manufactur
instruct
luminex
austin
tx
coupl
bead
pellet
resuspend
storag
buffer
x
ml
pb
bovin
serum
albumin
bsa
sodium
azid
ph
store
c
three
five
million
bead
prepar
singl
ml
conic
tube
bead
need
singl
run
beadswel
x
number
well
pellet
resuspend
assay
buffer
pb
bsa
volum
deliv
bead
well
aliquot
serum
dilut
assay
buffer
twice
desir
dilut
ad
well
contain
bead
incub
room
temperatur
hr
plate
shaker
rpm
two
wash
assay
buffer
biotinylatedantihuman
total
ig
abcam
catalog
ad
incub
min
room
temperatur
plate
shaker
two
wash
streptavidinphycoerythrin
pe
ad
biolegend
catalog
follow
min
incub
room
temperatur
plate
shaker
two
addit
wash
assay
bufferwel
ad
put
shaker
resuspend
bead
plate
read
luminex
flexmap
instrument
sampl
test
duplic
result
record
mean
fluoresc
intens
mfi
serum
use
experi
herein
previou
work
use
similar
format
serum
plasma
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
use
unpublish
data
sera
uninfect
individu
drawn
start
epidem
serv
neg
control
figur
gener
use
graphpad
prism
role
fund
sourc
fund
sourc
play
role
studi
design
collect
analysi
interpret
data
write
report
decis
submit
paper
public
correspond
author
confirm
full
access
data
studi
final
respons
decis
submit
public
eleven
serum
specimen
test
eight
differ
patient
confirm
infect
specimen
four
uninfect
individu
use
bank
part
ongo
longitudin
studi
prior
outbreak
assay
perform
bsl
lab
sinc
involv
live
viru
normal
blood
precaut
employ
handl
human
specimen
use
studi
serum
specimen
heat
inactiv
min
c
prior
use
assay
specimen
screen
presenc
ab
reactiv
solubl
recombin
trimer
mammalian
cell
express
protein
mspike
mrbd
figur
use
secondari
ab
detect
total
ig
patient
specimen
react
strongli
antigen
figur
although
reactiv
mspike
gener
stronger
mrbd
figur
consist
find
amanat
et
al
although
differ
sera
use
experi
three
sera
uninfect
patient
react
either
antigen
figur
reactiv
presenc
pb
serum
data
shown
notabl
studi
design
diagnost
accuraci
studi
least
specimen
would
need
includ
establish
signific
cutoff
valu
howev
strike
pcr
posit
specimen
ab
posit
mfi
valu
pcr
neg
specimen
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ab
neg
mfi
valu
determin
dynam
rang
assay
determin
titer
ab
present
sera
titrat
perform
specimen
use
mspike
antigen
seven
specimen
use
mrbd
antigen
three
specimen
uninfect
subject
titrat
antigen
titrat
curv
shown
figur
prozon
effect
phenomenon
valu
peak
observ
low
dilut
sera
suggest
curv
gener
six
sera
test
mspike
prozon
phenomenon
less
appar
use
mrbd
antigen
gener
maximum
mfi
valu
achiev
serum
dilut
level
ab
vari
greatli
specimen
test
exampl
mfi
valu
serum
dilut
infect
patient
rang
figur
interest
titrat
curv
show
specimen
highest
ab
level
p
p
two
differ
patient
p
p
two
subject
two
patient
sever
diseas
time
blood
draw
tabl
studi
need
ascertain
whether
diseas
sever
affect
level
type
ab
induc
howev
notabl
level
ab
increas
period
day
two
patient
longitudin
specimen
p
p
tabl
factor
affect
variat
ab
respons
sever
diseas
length
infect
gender
genet
etc
yet
determin
requir
larg
panel
specimen
patient
adequ
clinic
demograph
data
rapid
throughput
test
ab
luminex
bead
bind
ab
assay
describ
serv
essenti
tool
identifi
infect
individu
complement
pcrbase
method
measur
presenc
level
ab
assay
particularli
use
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
assay
identifi
individu
asymptomat
infect
includ
children
given
rel
high
preval
asymptomat
individu
infect
ab
assay
thu
fill
essenti
gap
current
pandem
sinc
luminex
ab
assay
perform
approxim
hr
figur
extrem
small
amount
antigen
per
test
platform
process
thousand
sampl
per
day
ab
assay
describ
use
antigenco
magnet
bead
prepar
bulk
use
least
four
week
simplifi
work
load
logist
laboratori
worth
note
use
variou
hiv
protein
peptid
use
antigenco
xmap
bead
store
steril
condit
describ
method
week
length
time
xmap
bead
coat
mspike
mrbd
protein
store
use
success
yet
determin
bar
degrad
protein
c
steril
condit
anticip
would
stabl
use
week
longer
mean
antigenco
bead
could
prepar
store
batch
provid
reagent
sever
thousand
test
concentr
bead
use
bead
coat
experi
describ
sinc
concentr
use
previous
variou
protein
concentr
bead
gave
compar
valu
bead
gave
lower
mfi
valu
titrat
curv
sera
infect
individu
data
shown
given
rbd
recombin
protein
current
limit
suppli
minimum
concentr
beadcoat
advantag
coat
ugmillion
bead
result
use
respectivelya
level
consider
less
requir
elisa
assay
modif
underway
determin
bodili
fluid
urin
andor
saliva
replac
serum
assay
urin
saliva
ab
test
use
diagnost
diseas
hiv
tb
assay
scale
use
hospit
refer
laboratori
high
throughput
assay
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
use
multitud
purpos
includ
serosurveil
commun
screen
health
care
worker
may
develop
immun
identif
donor
plasma
therapi
select
individu
potenti
immun
reinfect
extrem
grate
patient
contribut
research
wish
full
recoveri
none
author
current
financi
interest
person
relationship
person
relationship
would
constitut
conflict
interest
rivalri
academ
competit
intellectu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
belief
peopl
organ
icahn
school
medicin
mount
sinai
decid
submit
patent
applic
base
method
describ
herein
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
na
collect
oct
na
na
na
n
na
collect
nov
na
na
na
n
na
collect
oct
na
na
na
patient
specimen
p
deidentifi
na
applic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
titrat
neg
sera
specimen
dilut
dilut
test
use
luminex
assay
describ
herein
titrat
curv
shown
sera
specimen
eight
infect
patient
use
mspike
antigen
left
sera
three
patient
test
vs
mrbd
right
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
read
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
